Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Can methotrexate be safely taken with other medications?Lipitor and protein's interaction how?How often should liver function be checked while on ezetimibe?Does a patient's weight affect cosentyx dosage?How long until trametinib's patent rights expire?
See the DrugPatentWatch profile for tigecycline
Recommended Dosing for Tigecycline as a Single Agent The standard dose of tigecycline for single-agent use is 100 mg administered intravenously over a period of 30 minutes, followed by a 50 mg dose every 12 hours [1]. Duration of Therapy The optimal duration of tigecycline therapy is not well defined and should be tailored to the individual patient, taking into consideration the type and severity of infection, as well as patient-specific factors. However, tigecycline has been shown to be effective in treating infections caused by a variety of bacteria, including those resistant to other antibiotics [2]. Comparison to Other Options When compared to other antibiotics, such as vancomycin and ceftriaxone, tigecycline has been shown to have similar or improved efficacy in treating certain types of infections, such as complicated intra-abdominal infections [3]. However, more research is needed to fully understand the potential benefits and risks of tigecycline compared to other antibiotics. Dosing Considerations It's worth noting that tigecycline is typically dosed without regard to renal function, which may be beneficial for patients with kidney impairment [4]. However, the effect of tigecycline on patients with liver function impairment has not been well studied, and caution should be exercised in such patients. References [1] Tigecycline (Tygacil) prescribing information [5] [2] Tigecycline for the treatment of complicated skin and skin structure infections. (2005) [6] [3] Comparison of tigecycline and vancomycin in the treatment of complicated intra-abdominal infections. (2008) [7] [4] Tigecycline pharmacokinetics in patients with end-stage renal disease on hemodialysis. (2007) [8] [5] https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s022lbl.pdf [6] http://www.ncbi.nlm.nih.gov/pubmed/16337567 [7] http://www.ncbi.nlm.nih.gov/pubmed/17941544 [8] http://www.ncbi.nlm.nih.gov/pubmed/18223044
Other Questions About Tigecycline :